Investigators hope that their findings will assist in the development of targeted treatments for pediatric brain cancers.
Browsing: pediatric oncology
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
New research has elucidated a pathway in diffuse intrinsic pontine glioma with promise for therapeutic targeting.
A group of researchers from the Dana-Farber Cancer Institute (MA, USA) has conducted the largest clinical study to date of genetic abnormalities in pediatric brain tumors.
In this perspective article, the authors identify specific end points that should be included in the interpretation of clinical trial results and accordingly, offer a more comprehensive approach to treatment decision-making.
Tumors of the CNS are among the most common malignancies occurring in teenage/young adult patients but treatment of this patient population is challenging. This article reviews the opportunities for improving patient care in this population.